Skip to main content
Top
Published in: Diabetes Therapy 5/2018

Open Access 01-10-2018 | Review

Long-Term Effects of Oral Antidiabetic Drugs During Pregnancy on Offspring: A Systematic Review and Meta-analysis of Follow-up Studies of RCTs

Authors: Wenneke van Weelden, Vincent Wekker, Leon de Wit, Jacqueline Limpens, Hilkka Ijäs, Aleid G. van Wassenaer-Leemhuis, Tessa J. Roseboom, Bas B. van Rijn, J. Hans DeVries, Rebecca C. Painter

Published in: Diabetes Therapy | Issue 5/2018

Login to get access

Abstract

Introduction

Antidiabetic drugs (OADs) are increasingly prescribed to treat hyperglycaemia during pregnancy in women with gestational diabetes mellitus (GDM) or polycystic ovary syndrome (PCOS), even though long-term effects on offspring are unknown. This systematic review summarises the evidence of follow-up studies of randomised controlled trials (RCTs) reporting on long-term effects of prenatal exposure to OADs on offspring.

Methods

The MEDLINE, EMBASE and CENTRAL databases were searched from inception to April 2018 for the concepts antidiabetic agents and prenatal exposure (or pregnancy and offspring/child) in combination with an RCT search filter. RCTs evaluating post-neonatal health effects in offspring and comparing maternal treatment with an OAD with no treatment, placebo, an alternative OAD or insulin during pregnancy were eligible for inclusion. Two independent researchers selected, extracted and assessed the data. Meta-analyses were performed using a random effects model and the Cochrane Collaboration’s risk of bias tool was used for quality assessment.

Results

Ten studies were included, with a maximal follow-up duration of 9 years, comprising 778 children of mothers with GDM or PCOS who were randomised to either metformin or insulin/placebo during pregnancy. Meta-analysis showed that children prenatally exposed to metformin were heavier compared to controls (standardised mean difference (SMD) 0.26 [95% CI 0.11–0.41]), but not taller (SMD 0.10 [95% CI −0.14–0.33]). Additionally, offspring body mass index (BMI) z scores did not differ according to metformin exposure (mean difference 0.30 [95% CI −0.01–0.61]). Individual small studies reported that prenatal exposure to metformin was associated with greater mid-upper arm, head and waist circumferences, biceps skinfolds, waist-to-height ratio, more arm fat, higher fasting glucose, ferritin and lower LDL cholesterol in offspring.

Conclusion

Prenatal exposure to metformin is associated with increased offspring weight, but not with height or BMI. Larger follow-up studies are needed to confirm and look into the implications of these findings.

Plain Language Summary

Plain language summary available for this article.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zhu Y, Zhang C. Prevalence of gestational diabetes and risk of progression to type 2 diabetes: a global perspective. Curr Diabetes Rep. 2016;16(1):7.CrossRef Zhu Y, Zhang C. Prevalence of gestational diabetes and risk of progression to type 2 diabetes: a global perspective. Curr Diabetes Rep. 2016;16(1):7.CrossRef
2.
go back to reference Hod M, Kapur A, Sacks DA, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis, management, and care. Int J Gynecol Obstet. 2015;131:S173–211.CrossRef Hod M, Kapur A, Sacks DA, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis, management, and care. Int J Gynecol Obstet. 2015;131:S173–211.CrossRef
3.
go back to reference International Diabetes Federation. DF diabetes atlas, 8th edn. Brussels, Belgium. 2017. International Diabetes Federation. DF diabetes atlas, 8th edn. Brussels, Belgium. 2017.
4.
go back to reference Bimson BE, Rosenn BM, Morris SA, Sasso EB, Schwartz RA, Brustman LE. Current trends in the diagnosis and management of gestational diabetes mellitus in the United States. J Matern Fetal Neonatal Med. 2017;30:2607–2612.CrossRefPubMed Bimson BE, Rosenn BM, Morris SA, Sasso EB, Schwartz RA, Brustman LE. Current trends in the diagnosis and management of gestational diabetes mellitus in the United States. J Matern Fetal Neonatal Med. 2017;30:2607–2612.CrossRefPubMed
5.
go back to reference Coetzee EJ. Pregnancy and diabetes scenario around the world: Africa. Int J Gynecol Obstet. 2009;104(Supplement):S39–41.CrossRef Coetzee EJ. Pregnancy and diabetes scenario around the world: Africa. Int J Gynecol Obstet. 2009;104(Supplement):S39–41.CrossRef
6.
go back to reference The Guideline Development Group. Management of diabetes from preconception to the postnatal period: summary of NICE guidance. BMJ. 2008;336(7646):714–7.CrossRefPubMedCentral The Guideline Development Group. Management of diabetes from preconception to the postnatal period: summary of NICE guidance. BMJ. 2008;336(7646):714–7.CrossRefPubMedCentral
7.
go back to reference Brown J, Martis R, Hughes B, Rowan J, Crowther CA. Oral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes. Cochrane Database Syst Rev. 2017;1:CD011967. Brown J, Martis R, Hughes B, Rowan J, Crowther CA. Oral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes. Cochrane Database Syst Rev. 2017;1:CD011967.
8.
go back to reference Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ. 2015;350:h102.CrossRefPubMedPubMedCentral Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ. 2015;350:h102.CrossRefPubMedPubMedCentral
9.
go back to reference Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20(6):953–66.CrossRefPubMed Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20(6):953–66.CrossRefPubMed
10.
go back to reference De Oliveira Baraldi C, Lanchote VL, De Jesus Antunes N, De Carvalho TMJP, Dantes Moisés EC, Duarte G, et al. Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. Eur J Clin Pharmacol. 2011;67(10):1027–33.CrossRefPubMed De Oliveira Baraldi C, Lanchote VL, De Jesus Antunes N, De Carvalho TMJP, Dantes Moisés EC, Duarte G, et al. Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. Eur J Clin Pharmacol. 2011;67(10):1027–33.CrossRefPubMed
11.
go back to reference Schwartz RA, Rosenn B, Aleksa K, Koren G. Glyburide transport across the human placenta. Obstet Gynecol. 2015;125(3):583–8.CrossRefPubMed Schwartz RA, Rosenn B, Aleksa K, Koren G. Glyburide transport across the human placenta. Obstet Gynecol. 2015;125(3):583–8.CrossRefPubMed
12.
go back to reference Charles B, Norris R, Xiao X, Hague W. Population pharmacokinetics of metformin in late pregnancy. Ther Drug Monit. 2006;28(1):67–72.CrossRefPubMed Charles B, Norris R, Xiao X, Hague W. Population pharmacokinetics of metformin in late pregnancy. Ther Drug Monit. 2006;28(1):67–72.CrossRefPubMed
13.
go back to reference Vanky E, Zahlsen K, Spigset O, Carlsen SM. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril. 2005;83(5):1575–8.CrossRefPubMed Vanky E, Zahlsen K, Spigset O, Carlsen SM. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril. 2005;83(5):1575–8.CrossRefPubMed
14.
go back to reference Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril. 2006;86(3):658–63.CrossRefPubMed Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril. 2006;86(3):658–63.CrossRefPubMed
15.
go back to reference Cassina M, Donà M, Di Gianantonio E, Litta P, Clementi M. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):656–69.CrossRefPubMed Cassina M, Donà M, Di Gianantonio E, Litta P, Clementi M. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):656–69.CrossRefPubMed
17.
go back to reference Barker DJP. The origins of the developmental origins theory. J Intern Med. 2007;261(5):412–7.CrossRef Barker DJP. The origins of the developmental origins theory. J Intern Med. 2007;261(5):412–7.CrossRef
18.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRefPubMedPubMedCentral Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.CrossRefPubMedPubMedCentral
19.
go back to reference Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Higgins JPT, Green S, editors: The Cochrane Collaboration, 2011; 2011. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Higgins JPT, Green S, editors: The Cochrane Collaboration, 2011; 2011.
20.
go back to reference Glanville JM, Lefebvre C, Miles JNV, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. J Med Libr Assoc. 2006;94(2):130–6.PubMedPubMedCentral Glanville JM, Lefebvre C, Miles JNV, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. J Med Libr Assoc. 2006;94(2):130–6.PubMedPubMedCentral
21.
go back to reference Hayes R, Dennerstein L. The impact of aging on sexual function and sexual dysfunction in women: a review of population-based studies. J Sex Med. 2005;2(3):317–30.CrossRefPubMed Hayes R, Dennerstein L. The impact of aging on sexual function and sexual dysfunction in women: a review of population-based studies. J Sex Med. 2005;2(3):317–30.CrossRefPubMed
22.
23.
go back to reference Ryan R, Hill S. How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group. December 2016; Version 3.0. Ryan R, Hill S. How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group. December 2016; Version 3.0.
24.
go back to reference Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111.CrossRefPubMed Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111.CrossRefPubMed
25.
go back to reference Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. Diabetes Care. 2011;34(10):2279–84.CrossRefPubMedPubMedCentral Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. Diabetes Care. 2011;34(10):2279–84.CrossRefPubMedPubMedCentral
26.
go back to reference Battin MR, Obolonkin V, Rush E, Hague W, Coat S, Rowan J. Blood pressure measurement at two years in offspring of women randomized to a trial of metformin for GDM: follow up data from the MiG trial. BMC Pediatr. 2015;15(1):54.CrossRefPubMedPubMedCentral Battin MR, Obolonkin V, Rush E, Hague W, Coat S, Rowan J. Blood pressure measurement at two years in offspring of women randomized to a trial of metformin for GDM: follow up data from the MiG trial. BMC Pediatr. 2015;15(1):54.CrossRefPubMedPubMedCentral
27.
go back to reference Wouldes TA, Battin M, Coat S, Rush EC, Hague WM, Rowan JA. Neurodevelopmental outcome at 2 years in offspring of women randomised to metformin or insulin treatment for gestational diabetes. Arch Dis Child Fetal Neonatal Ed. 2016;101:F488–93.CrossRef Wouldes TA, Battin M, Coat S, Rush EC, Hague WM, Rowan JA. Neurodevelopmental outcome at 2 years in offspring of women randomised to metformin or insulin treatment for gestational diabetes. Arch Dis Child Fetal Neonatal Ed. 2016;101:F488–93.CrossRef
28.
go back to reference Carlsen SM, Martinussen MP, Vanky E. Metformin’s effect on first-year weight gain: a follow-up study. Pediatrics. 2012;130(5):e1222–6.CrossRefPubMed Carlsen SM, Martinussen MP, Vanky E. Metformin’s effect on first-year weight gain: a follow-up study. Pediatrics. 2012;130(5):e1222–6.CrossRefPubMed
29.
go back to reference Ijäs H, Vaarasmaki M, Saarela T, Keravuo R, Raudaskoski T. A follow-up of a randomised study of metformin and insulin in gestational diabetes mellitus: growth and development of the children at the age of 18 months. BJOG. 2015;122(7):994–1000.CrossRefPubMed Ijäs H, Vaarasmaki M, Saarela T, Keravuo R, Raudaskoski T. A follow-up of a randomised study of metformin and insulin in gestational diabetes mellitus: growth and development of the children at the age of 18 months. BJOG. 2015;122(7):994–1000.CrossRefPubMed
30.
go back to reference Tertti K, Eskola E, Rönnemaa T, Haataja L. Neurodevelopment of two-year-old children exposed to metformin and insulin in gestational diabetes mellitus. J Dev Behav Pediatr. 2015;36(9):752–7.CrossRefPubMed Tertti K, Eskola E, Rönnemaa T, Haataja L. Neurodevelopment of two-year-old children exposed to metformin and insulin in gestational diabetes mellitus. J Dev Behav Pediatr. 2015;36(9):752–7.CrossRefPubMed
31.
go back to reference Tertti K, Toppari J, Virtanen HE, Sadov STR. Metformin treatment does not affect testicular size in offspring born to mothers with gestational diabetes. Rev Diabet Stud. 2016;13(1):59–65.CrossRefPubMedPubMedCentral Tertti K, Toppari J, Virtanen HE, Sadov STR. Metformin treatment does not affect testicular size in offspring born to mothers with gestational diabetes. Rev Diabet Stud. 2016;13(1):59–65.CrossRefPubMedPubMedCentral
32.
go back to reference Rø TB, Ludvigsen HV, Carlsen SM, Vanky E. Growth, body composition and metabolic profile of 8-year-old children exposed to metformin in utero. Scand J Clin Lab Invest. 2012;72(7):570–5.CrossRefPubMed Rø TB, Ludvigsen HV, Carlsen SM, Vanky E. Growth, body composition and metabolic profile of 8-year-old children exposed to metformin in utero. Scand J Clin Lab Invest. 2012;72(7):570–5.CrossRefPubMed
33.
go back to reference Rowan JA, Rush EC, Plank LD, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age. BMJ Open Diabetes Res Care. 2018;6(1):e000456.CrossRefPubMedPubMedCentral Rowan JA, Rush EC, Plank LD, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age. BMJ Open Diabetes Res Care. 2018;6(1):e000456.CrossRefPubMedPubMedCentral
34.
go back to reference Hanem LGE, Stridsklev S, Júlíusson PB, et al. Metformin use in PCOS pregnancies increases the risk of offspring overweight at 4 years of age: follow-up of two RCTs. J Clin Endocrinol Metab. 2018;103(4):1612–21.CrossRefPubMed Hanem LGE, Stridsklev S, Júlíusson PB, et al. Metformin use in PCOS pregnancies increases the risk of offspring overweight at 4 years of age: follow-up of two RCTs. J Clin Endocrinol Metab. 2018;103(4):1612–21.CrossRefPubMed
35.
go back to reference Chiswick CA, Reynolds RM, Denison FC, et al. Efficacy of metformin in pregnant obese women: a randomised controlled trial. BMJ Open. 2015;5(1):e006854.CrossRefPubMedPubMedCentral Chiswick CA, Reynolds RM, Denison FC, et al. Efficacy of metformin in pregnant obese women: a randomised controlled trial. BMJ Open. 2015;5(1):e006854.CrossRefPubMedPubMedCentral
36.
go back to reference Feig DS, Murphy K, Asztalos E, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial. BMC Pregnancy Childbirth. 2016;16(1):173.CrossRefPubMedPubMedCentral Feig DS, Murphy K, Asztalos E, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial. BMC Pregnancy Childbirth. 2016;16(1):173.CrossRefPubMedPubMedCentral
37.
go back to reference Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010;95(12):E448–55.CrossRefPubMed Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010;95(12):E448–55.CrossRefPubMed
38.
go back to reference Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003–15.CrossRefPubMed Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003–15.CrossRefPubMed
39.
go back to reference Ijäs H, Vääräsmäki M, Morin-Papunen L, et al. Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study. BJOG Int J Obstet Gynaecol. 2011;118(7):880–5.CrossRef Ijäs H, Vääräsmäki M, Morin-Papunen L, et al. Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study. BJOG Int J Obstet Gynaecol. 2011;118(7):880–5.CrossRef
40.
go back to reference Tertti K, Ekblad U, Koskinen P, Vahlberg T, Rönnemaa T. Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin. Diabetes Obes Metab. 2013;15(3):246–51.CrossRefPubMed Tertti K, Ekblad U, Koskinen P, Vahlberg T, Rönnemaa T. Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin. Diabetes Obes Metab. 2013;15(3):246–51.CrossRefPubMed
41.
go back to reference Vanky E, Salvesen KÅ, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod. 2004;19(8):1734–40.CrossRefPubMed Vanky E, Salvesen KÅ, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod. 2004;19(8):1734–40.CrossRefPubMed
42.
go back to reference Dewailly D, Tarlatzis R. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.CrossRef Dewailly D, Tarlatzis R. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.CrossRef
43.
go back to reference WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. Geneva: World Health Organization, 2006. p. 312 WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. Geneva: World Health Organization, 2006. p. 312
44.
go back to reference Salomäki H, Vähätalo LH, Laurila K, et al. Prenatal metformin exposure in mice programs the metabolic phenotype of the offspring during a high fat diet at adulthood. PLoS One. 2013;8(2):e56594.CrossRefPubMedPubMedCentral Salomäki H, Vähätalo LH, Laurila K, et al. Prenatal metformin exposure in mice programs the metabolic phenotype of the offspring during a high fat diet at adulthood. PLoS One. 2013;8(2):e56594.CrossRefPubMedPubMedCentral
45.
go back to reference Lee H-S. Impact of maternal diet on the epigenome during in utero life and the developmental programming of diseases in childhood and adulthood. Nutrients. 2015;7(11):9492–507.CrossRefPubMedPubMedCentral Lee H-S. Impact of maternal diet on the epigenome during in utero life and the developmental programming of diseases in childhood and adulthood. Nutrients. 2015;7(11):9492–507.CrossRefPubMedPubMedCentral
46.
go back to reference Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor–social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod. 2004;19(6):1323–30.CrossRefPubMed Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor–social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod. 2004;19(6):1323–30.CrossRefPubMed
47.
go back to reference Guo SS, Wu W, Chumlea WC, Roche AF. Predicting overweight and obesity in adulthood from body mass index values in childhood and adolescence. Am J Clin Nutr. 2002;76(3):653–8.CrossRefPubMed Guo SS, Wu W, Chumlea WC, Roche AF. Predicting overweight and obesity in adulthood from body mass index values in childhood and adolescence. Am J Clin Nutr. 2002;76(3):653–8.CrossRefPubMed
48.
go back to reference Simmonds M, Llewellyn A, Owen CG, Woolacott N. Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. Obes Rev. 2015;17(2):95–107.CrossRefPubMed Simmonds M, Llewellyn A, Owen CG, Woolacott N. Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. Obes Rev. 2015;17(2):95–107.CrossRefPubMed
49.
go back to reference Field AE, Cook NR, Gillman MW. Weight status in childhood as a predictor of becoming overweight or hypertensive in early adulthood. Obes Res. 2005;13(1):163–9.CrossRefPubMedPubMedCentral Field AE, Cook NR, Gillman MW. Weight status in childhood as a predictor of becoming overweight or hypertensive in early adulthood. Obes Res. 2005;13(1):163–9.CrossRefPubMedPubMedCentral
50.
go back to reference Hertz-Picciotto I, Pastore LM, Beaumont JJ. Timing and patterns of exposures during pregnancy and their implications for study methods. Am J Epidemiol. 1996;143(6):597–607.CrossRefPubMed Hertz-Picciotto I, Pastore LM, Beaumont JJ. Timing and patterns of exposures during pregnancy and their implications for study methods. Am J Epidemiol. 1996;143(6):597–607.CrossRefPubMed
51.
go back to reference Fewtrell MS, Kennedy K, Singhal A, et al. How much loss to follow-up is acceptable in long-term randomised trials and prospective studies? Arch Dis Child. 2008;93(6):458–61.CrossRefPubMed Fewtrell MS, Kennedy K, Singhal A, et al. How much loss to follow-up is acceptable in long-term randomised trials and prospective studies? Arch Dis Child. 2008;93(6):458–61.CrossRefPubMed
Metadata
Title
Long-Term Effects of Oral Antidiabetic Drugs During Pregnancy on Offspring: A Systematic Review and Meta-analysis of Follow-up Studies of RCTs
Authors
Wenneke van Weelden
Vincent Wekker
Leon de Wit
Jacqueline Limpens
Hilkka Ijäs
Aleid G. van Wassenaer-Leemhuis
Tessa J. Roseboom
Bas B. van Rijn
J. Hans DeVries
Rebecca C. Painter
Publication date
01-10-2018
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 5/2018
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-018-0479-0

Other articles of this Issue 5/2018

Diabetes Therapy 5/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.